Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Monday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price for the company.

Lipocine Stock Down 0.6 %

NASDAQ LPCN opened at $4.99 on Monday. The company has a fifty day moving average of $5.17 and a two-hundred day moving average of $5.51. The firm has a market capitalization of $26.69 million, a price-to-earnings ratio of -6.57 and a beta of 1.24. Lipocine has a 52 week low of $2.44 and a 52 week high of $11.79.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Lipocine will post -0.78 EPS for the current year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC grew its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.